Literature DB >> 2267923

Growth hormone secretion in Prader-Willi syndrome.

H Costeff1, V A Holm, R Ruvalcaba, J Shaver.   

Abstract

Integrated 12-hour growth hormone secretion studies, peak growth hormone response to clonidine provocation. Somatomedin-C levels, T-4 and TSH levels were studied in six growth-retarded children with the Prader-Willi syndrome, of whom five had a 15 q-karyotype. Only one of the subjects was obese. All showed abnormally low growth hormone secretion. None achieved a nocturnal peak above 10 micrograms/l, none had a mean nocturnal level over 1.8, and none showed a level above 8 micrograms/l after clonidine provocation. These findings contrasted with normal TSH in all and normal T-4 in five. These findings suggest that the poor linear growth in the Prader-Willi syndrome is caused by a true deficiency of growth hormone secretion, and that the low growth hormone levels observed in such cases are not an artifact of obesity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2267923     DOI: 10.1111/j.1651-2227.1990.tb11383.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  17 in total

1.  Effect of growth hormone on height, weight, and body composition in Prader-Willi syndrome.

Authors:  P S Davies; S Evans; S Broomhead; H Clough; J M Day; A Laidlaw; N D Barnes
Journal:  Arch Dis Child       Date:  1998-05       Impact factor: 3.791

2.  Impairment of adipose tissue in Prader-Willi syndrome rescued by growth hormone treatment.

Authors:  T Cadoudal; M Buléon; C Sengenès; G Diene; F Desneulin; C Molinas; S Eddiry; F Conte-Auriol; D Daviaud; P G P Martin; A Bouloumié; J-P Salles; M Tauber; P Valet
Journal:  Int J Obes (Lond)       Date:  2014-01-10       Impact factor: 5.095

3.  GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology.

Authors:  A Corrias; J Bellone; L Beccaria; L Bosio; G Trifirò; C Livieri; L Ragusa; A Salvatoni; M Andreo; P Ciampalini; G Tonini; A Crinò
Journal:  J Endocrinol Invest       Date:  2000-02       Impact factor: 4.256

4.  Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome.

Authors:  G Grugni; G Guzzaloni; F Morabito
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

Review 5.  Paediatrics--Part I.

Authors:  B L Priestley; C J Harrison; M P Gerrard; A Gibson
Journal:  Postgrad Med J       Date:  1993-03       Impact factor: 2.401

Review 6.  The Prader-Willi syndrome.

Authors:  M D Donaldson; C E Chu; A Cooke; A Wilson; S A Greene; J B Stephenson
Journal:  Arch Dis Child       Date:  1994-01       Impact factor: 3.791

7.  Treatment with human growth hormone in patients with Prader-Labhart-Willi syndrome reduces body fat and increases muscle mass and physical performance.

Authors:  U Eiholzer; R Gisin; C Weinmann; S Kriemler; H Steinert; T Torresani; M Zachmann; A Prader
Journal:  Eur J Pediatr       Date:  1998-05       Impact factor: 3.183

8.  Clinical management of behavioral characteristics of Prader-Willi syndrome.

Authors:  Alan Y Ho; Anastasia Dimitropoulos
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

9.  The growth hormone response to hexarelin in patients with Prader-Willi syndrome.

Authors:  M Cappa; G Raguso; T Palmiotto; A Faedda; F Gurreri; G Neri; R Deghenghi; S Loche
Journal:  J Endocrinol Invest       Date:  1998-09       Impact factor: 4.256

10.  Long-term growth hormone therapy changes the natural history of body composition and motor function in children with prader-willi syndrome.

Authors:  Aaron L Carrel; Susan E Myers; Barbara Y Whitman; Jens Eickhoff; David B Allen
Journal:  J Clin Endocrinol Metab       Date:  2010-01-08       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.